Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Status
- RECRUITING
- Phase
- PHASE3
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Obinutuzumab in Primary MN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Status
- RECRUITING
- Phase
- PHASE2
Obinutuzumab in Primary FSGS
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
- Status
- UNKNOWN
- Phase
- PHASE2
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
- Status
- RECRUITING
- Phase
- PHASE2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE2
CAR-T Followed by Bispecific Antibodies
- Status
- RECRUITING
- Phase
- PHASE2
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Avo In R/R And Previously Untreated MCL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safe Accelerated Venetoclax Escalation in CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1